Eli Lilly and Company Closed Now

Introduction
Eli Lilly and Company is a global pharmaceutical firm headquartered in Indianapolis, USA. Founded in 1876 by Colonel Eli Lilly, the company has become one of the world’s most innovative drug makers, known for developing medicines in neuroscience, oncology, endocrinology, and immunology. In recent years, Eli Lilly has gained worldwide recognition for its breakthroughs in diabetes care, cancer treatments, and obesity management therapies.

Mission and Vision

• Mission: To unite caring with discovery to create medicines that make life better for people around the world.

• Vision: To improve lives globally through innovative medicines and leadership in critical therapeutic areas.

Products and Services

• Diabetes & Obesity: Insulin products and incretin-based therapies such as Mounjaro and Trulicity, revolutionizing obesity and diabetes management.

• Oncology: Innovative cancer treatments including Verzenio and Cyramza.

• Immunology: Therapies for autoimmune diseases like Olumiant (baricitinib).

• Neuroscience: Medicines for migraine, depression, and Alzheimer’s disease research.

• Animal Health (formerly Elanco): Previously provided animal health products (spun off in 2018).

Growth and Innovation
Eli Lilly has invested heavily in research for metabolic disorders, oncology, and neuroscience. The company has become a global leader in obesity and diabetes innovation with its incretin-based therapies, which are projected to transform patient care. Lilly is also advancing Alzheimer’s research with potential disease-modifying therapies. Its pipeline reflects a strong commitment to biologics and next-generation medicines.

Global Impact
With medicines marketed in more than 120 countries, Eli Lilly has a significant presence worldwide. Its diabetes and obesity portfolio has had a profound impact on public health, while its oncology and neuroscience breakthroughs continue to shape modern medicine. The company is also committed to affordability initiatives and global health partnerships to expand access to essential treatments